SLC7A6OS

Across TCGA pan-cancer cohorts, SLC7A6OS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC7A6OS data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC7A6OS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC7A6OS expression acts as an unfavorable survival marker.

LUAD, LIHC, and SKCM are the cancer types where SLC7A6OS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
SKCM	DFS	Median	All	0.192	0.737	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC7A6OS–LUAD (DFS)

Open the LUAD breakdown →